The role of HLA-G for protection of human renal cell-carcinoma cells from immune-mediated lysis: implications for immunotherapies

被引:19
作者
Bukur, E [1 ]
Seliger, B [1 ]
机构
[1] Johannes Gutenberg Univ Mainz, Dept Internal Med 3, D-55101 Mainz, Germany
关键词
non-classical HLA class I molecules; immune response; renal cell carcinoma; immunotherapy;
D O I
10.1016/S1044-579X(03)00026-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
HLA-G as a non-classical MHC class I molecule exhibits a limited tissue distribution and exerts multiple immune regulatory functions including the induction of immune tolerance. In addition, HLA-G has been detected in some tumors of different histology and therefore may represent a novel immune escape mechanism of tumor cells. Despite the immunogenicity of renal cell carcinoma (RCC), outgrowth of tumor cells occurs which might be attributable to abrogation of efficient anti-tumor responses. We here review the potential role of HLA-G in RCC immunology, the HLA-G expression pattern and its functional consequences on immune responses. A heterogenous constitutive and interferon-gamma inducible HLA-G mRNA and protein expression was found in RCC cell lines and tumor lesions, but not in autologous normal kidney epithelium. HLA-G transcription and protein expression was detected at a high frequency in primary RCC lesions and RCC cell lines. Functional studies performed with alloreactive natural and lymphokine activated killer cells as well as antigen-specific CD8(+) T cell populations demonstrated that HLA-G expression inhibits lysis of RCC cells by these different immune effector cells, whereas HLA-G(-) normal kidney cells were recognized. Thus, aberrant HLA-G expression might participate in evasion of these tumor cells from immunosurveillance. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:353 / 359
页数:7
相关论文
共 45 条
[1]   CELLULAR IMMUNE-RESPONSE TO HUMAN RENAL-CELL CARCINOMAS - DEFINITION OF A COMMON ANTIGEN RECOGNIZED BY HLA-A2-RESTRICTED CYTOTOXIC T-LYMPHOCYTE (CTL) CLONES [J].
BERNHARD, H ;
KARBACH, J ;
WOLFEL, T ;
BUSCH, P ;
STORKEL, S ;
STOCKLE, M ;
WOLFEL, C ;
SELIGER, B ;
HUBER, C ;
ZUMBUSCHENFELDE, KHM ;
KNUTH, A .
INTERNATIONAL JOURNAL OF CANCER, 1994, 59 (06) :837-842
[2]   Immunotherapy of urologic tumors: principles and progress [J].
Broghammer, EL ;
Ratliff, TL .
UROLOGIC ONCOLOGY, 2002, 7 (02) :45-56
[3]  
Bukowski RM, 1998, CLIN CANCER RES, V4, P2337
[4]  
BUKUR J, IN PRESS CANC RES
[5]   HLA-G and HLA-E: fundamental and pathophysiological aspects [J].
Carosella, ED ;
Paul, P ;
Moreau, P ;
Rouas-Freiss, N .
IMMUNOLOGY TODAY, 2000, 21 (11) :532-534
[6]  
CORDONCARDO C, 1991, CANCER RES, V51, P6372
[7]   Renal cell carcinoma: Management of advanced disease [J].
Figlin, RA .
JOURNAL OF UROLOGY, 1999, 161 (02) :381-386
[8]   CHARACTERIZATION OF TUMOR-INFILTRATING LYMPHOCYTE SUBSETS FROM HUMAN RENAL-CELL CARCINOMA - SPECIFIC REACTIVITY DEFINED BY CYTOTOXICITY, INTERFERON-GAMMA SECRETION, AND PROLIFERATION [J].
FINKE, JH ;
RAYMAN, P ;
HART, L ;
ALEXANDER, JP ;
EDINGER, MG ;
TUBBS, RR ;
KLEIN, E ;
TUASON, L ;
BUKOWSKI, RM .
JOURNAL OF IMMUNOTHERAPY, 1994, 15 (02) :91-104
[9]  
FINKE JH, 1993, CANCER RES, V53, P5613
[10]   Soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8 [J].
Fournel, S ;
Aguerre-Girr, M ;
Huc, X ;
Lenfant, F ;
Alam, A ;
Toubert, A ;
Bensussan, A ;
Le Bouteiller, P .
JOURNAL OF IMMUNOLOGY, 2000, 164 (12) :6100-6104